575 related articles for article (PubMed ID: 32616205)
1. Ketamine for depression clinical issues.
Iqbal SZ; Mathew SJ
Adv Pharmacol; 2020; 89():131-162. PubMed ID: 32616205
[TBL] [Abstract][Full Text] [Related]
2. An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine.
De Berardis D; Tomasetti C; Pompili M; Serafini G; Vellante F; Fornaro M; Valchera A; Perna G; Volpe U; Martinotti G; Fraticelli S; Di Giannantonio M; Kim YK; Orsolini L
Curr Top Med Chem; 2020; 20(7):554-584. PubMed ID: 32003691
[TBL] [Abstract][Full Text] [Related]
3. Esketamine: A Novel Option for Treatment-Resistant Depression.
Bozymski KM; Crouse EL; Titus-Lay EN; Ott CA; Nofziger JL; Kirkwood CK
Ann Pharmacother; 2020 Jun; 54(6):567-576. PubMed ID: 31795735
[No Abstract] [Full Text] [Related]
4. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
[TBL] [Abstract][Full Text] [Related]
5. Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants.
Singh JB; Fedgchin M; Daly EJ; Drevets WC
Adv Pharmacol; 2020; 89():237-259. PubMed ID: 32616208
[TBL] [Abstract][Full Text] [Related]
6. Ketamine for depression.
Jelen LA; Stone JM
Int Rev Psychiatry; 2021 May; 33(3):207-228. PubMed ID: 33569971
[TBL] [Abstract][Full Text] [Related]
7. Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review.
Molero P; Ramos-Quiroga JA; Martin-Santos R; Calvo-Sánchez E; Gutiérrez-Rojas L; Meana JJ
CNS Drugs; 2018 May; 32(5):411-420. PubMed ID: 29736744
[TBL] [Abstract][Full Text] [Related]
8. Exploring Esketamine's Therapeutic Outcomes as an FDA-Designated Breakthrough for Treatment-Resistant Depression and Major Depressive Disorder With Suicidal Intent: A Narrative Review.
Kumari S; Chaudhry HA; Sagot A; Doumas S; Abdullah H; Alcera E; Solhkhah R; Afzal S
Cureus; 2024 Feb; 16(2):e53987. PubMed ID: 38476783
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
[TBL] [Abstract][Full Text] [Related]
10. Repurposing of Drugs-The Ketamine Story.
Das J
J Med Chem; 2020 Nov; 63(22):13514-13525. PubMed ID: 32915563
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine.
Hashimoto K
Biochem Pharmacol; 2020 Jul; 177():113935. PubMed ID: 32224141
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
[TBL] [Abstract][Full Text] [Related]
13. Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety.
Szarmach J; Cubała WJ; Włodarczyk A; Wiglusz MS
Psychiatr Danub; 2019 Sep; 31(Suppl 3):585-590. PubMed ID: 31488795
[TBL] [Abstract][Full Text] [Related]
14. Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine.
Chang L; Zhang K; Pu Y; Qu Y; Wang SM; Xiong Z; Ren Q; Dong C; Fujita Y; Hashimoto K
Pharmacol Biochem Behav; 2019 Jun; 181():53-59. PubMed ID: 31034852
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for Major depression: A systematic review and meta-analysis.
Seshadri A; Prokop LJ; Singh B
J Affect Disord; 2024 Jul; 356():379-384. PubMed ID: 38537759
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder.
Kryst J; Kawalec P; Pilc A
Expert Opin Pharmacother; 2020 Jan; 21(1):9-20. PubMed ID: 31663783
[No Abstract] [Full Text] [Related]
17. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
Wajs E; Aluisio L; Holder R; Daly EJ; Lane R; Lim P; George JE; Morrison RL; Sanacora G; Young AH; Kasper S; Sulaiman AH; Li CT; Paik JW; Manji H; Hough D; Grunfeld J; Jeon HJ; Wilkinson ST; Drevets WC; Singh JB
J Clin Psychiatry; 2020 Apr; 81(3):. PubMed ID: 32316080
[TBL] [Abstract][Full Text] [Related]
18. Switching to Intranasal Esketamine Maintains the Antidepressant Response to Intravenous Racemic Ketamine Administration: A Case Series of 10 Patients.
Banov MD; Landrum RE; Moore MB; Szabo ST
J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):594-599. PubMed ID: 34411009
[TBL] [Abstract][Full Text] [Related]
19. Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program.
Doherty T; Wajs E; Melkote R; Miller J; Singh JB; Weber MA
CNS Drugs; 2020 Mar; 34(3):299-310. PubMed ID: 31994024
[TBL] [Abstract][Full Text] [Related]
20. Ketamine and nitrous oxide: The evolution of NMDA receptor antagonists as antidepressant agents.
Kalmoe MC; Janski AM; Zorumski CF; Nagele P; Palanca BJ; Conway CR
J Neurol Sci; 2020 May; 412():116778. PubMed ID: 32240970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
